Comparison · NCT04673214-deaths
Dual Therapy Adverse Event vs Adverse Event Triple Therapy: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dual Therapy Adverse Event vs Adverse Event Triple Therapy: deaths from any cause. Trial comparisons, record NCT04673214-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04673214-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0217 | 0.00385 | 0.113 | wilson | |
| Risk in group 2 | 0.0308 | 0.00848 | 0.105 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00903 | -0.0858 | 0.0853 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.707 | 0.066 | 7.56 | log | |
| Odds ratio, group 1 over group 2 | 0.7 | 0.0616 | 7.96 | log | |
| Number needed to treat, for one fewer death from any cause on Dual Therapy Adverse Event than on Adverse Event Triple Therapy | 111 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dual Therapy Adverse Event | Record of adverse reactions of Blood and lymphatic system disorders, Heartdisorders, Ear and labyrinth disorders,Gastrointestinal disorders and Musculoskeletal and connective tissue disorders with the following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C. | 1 | 46 | EG000 |
| Group 2 | Adverse Event Triple Therapy | Record of adverse reactions of Blood and lymphatic system disorders, Heartdisorders, Ear and labyrinth disorders,Gastrointestinal disorders and Musculoskeletal and connective tissue disorders with the following medications were taken for this group: Azithromycin 500 mg tablets take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days; Ivermectin 6 mg tablets take as follows 2 TABLETS \<80 KG orally, 3 TABLETS between 80-110 kg orally, 4 TABLETS\> 110kg orally, every 24 hours for 2 days; Rivaroxaban 10 mg tablets take 1 every 24 hours for 10 days; Paracetamol 500 mg orally take 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C. | 2 | 65 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse event data was collected was 14 days.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
- NCT number
- NCT04673214
- Phases
- PHASE3
- Conditions
- Covid19
- Interventions
- Azithromycin / Ivermectin / Ribaroxaban / Paracetamol, Azithromycin / Ribaroxaban / Paracetamol
- Lead sponsor
- Gilberto Cruz Arteaga
- Results first posted
- 2021-08-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04673214?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04673214-deaths